Phenoconversion due to drug–drug interactions in CYP2C19 genotyped healthy volunteers
K Abouir, N Exquis, Y Gloor, Y Daali… - Clinical Pharmacology …, 2024 - Wiley Online Library
To compensate for drug response variability, drug metabolism phenotypes are determined
based on the results of genetic testing, and if necessary, drug dosages are adjusted. In …
based on the results of genetic testing, and if necessary, drug dosages are adjusted. In …
Pharmacogenetic guided drug therapy-how to deal with phenoconversion in polypharmacy?
JC Stingl, R Viviani - Expert Opinion on Drug Metabolism & …, 2025 - Taylor & Francis
Introduction The prevalence of polypharmacy and the increasing availability of
pharmacogenetic information in clinical practice have raised the prospect of data-driven …
pharmacogenetic information in clinical practice have raised the prospect of data-driven …
Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections
M Resztak, P Zalewska, J Wachowiak… - European Journal of …, 2024 - Springer
Purpose Therapeutic drug monitoring (TDM) of voriconazole (VCZ) should be mandatory for
all pediatric patients with invasive fungal infections (IFIs). The narrow therapeutic index, inter …
all pediatric patients with invasive fungal infections (IFIs). The narrow therapeutic index, inter …
[HTML][HTML] Managing drug–drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants
F Ricci, LV Molinari, D Mansour, K Galanti, F Vagnarelli… - Heart Rhythm, 2024 - Elsevier
Mavacamten is a selective, allosteric, and reversible cardiac myosin inhibitor, representing
the first disease-specific treatment for obstructive hypertrophic cardiomyopathy (HCM) that …
the first disease-specific treatment for obstructive hypertrophic cardiomyopathy (HCM) that …
CYP P450 and non-CYP P450 Drug Metabolizing Enzyme Families Exhibit Differential Sensitivities towards Proinflammatory Cytokine Modulation
LM de Jong, C Harpal, DJ van den Berg… - Drug Metabolism and …, 2024 - Elsevier
Compromised hepatic drug metabolism in response to proinflammatory cytokine release is
primarily attributed to downregulation of cytochrome P450 (CYP) enzymes. However …
primarily attributed to downregulation of cytochrome P450 (CYP) enzymes. However …
A type of self-assembled and label-free DNA-modified electrochemical biosensors based on magnetic α-Fe2O3/Fe3O4 heterogeneous nanorods for ultra-sensitive …
S Zhao, P Deng, M Ma, Z Xu, A He, R Liu - Bioelectrochemistry, 2024 - Elsevier
Abstract CYP2C19* 3 enzyme plays a pivotal role in drug metabolism and is tightly
regulated by the CYP2C19* 3 gene. Therefore, quantification of CYP2C19* 3 gene holds …
regulated by the CYP2C19* 3 gene. Therefore, quantification of CYP2C19* 3 gene holds …
Preparation, in vitro and in silico antioxidant and antibacterial studies of 4-aminoacetanilide azo derivatives
A new series of new 4-aminoacetanilide azo derivatives 1–13 were successfully synthesised
via a diazo coupling reaction and gave a good to excellent yield of 73%–93%. The …
via a diazo coupling reaction and gave a good to excellent yield of 73%–93%. The …
[HTML][HTML] Abstracts of the XVth Symposium of the Task Force Therapeutic Drug...: The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical …
M Scherf-Clavel, H Weber, S Unterecker… - …, 2024 - ncbi.nlm.nih.gov
Abstract Introduction CYP2D6 and CYP2C19 functional status as defined by genotype is
modulated by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there …
modulated by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there …
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics
M Scherf-Clavel, H Weber, S Unterecker… - …, 2024 - thieme-connect.com
Introduction CYP2D6 and CYP2C19 functional status as defined by genotype is modulated
by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there is no data …
by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there is no data …
Evaluation of CYP2C19 Genetic Variant and Its Lack of Association with Valproic Acid Plasma Concentrations Among Zhuang and Han Schizophrenia Patients in …
JM Teng, S Qin, D Lu, Y Gu, SJ Tang… - Pharmacogenomics …, 2024 - Taylor & Francis
Purpose To investigate the CYP2C19 genotype distribution and allelic frequency among the
Zhuang and Han schizophrenic populations in Guangxi, examine the correlation between …
Zhuang and Han schizophrenic populations in Guangxi, examine the correlation between …